Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer

• Published in: Gynecologic oncology 2004-08, Vol.94 (2), p.325-332
• Main Authors: Ryu, Ki Sung, Kim, Jae Hoon, Ko, Hyun Sun, Kim, Jin Woo, Ahn, Woong Shick, Park, Yong Gyu, Kim, Seung Jo, Lee, Joon Mo
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Carboplatin - administration & dosage; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Interferon-alpha - administration & dosage; Intraperitoneal hyperthermic chemotherapy (IPHC); Middle Aged; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Ovarian Neoplasms - surgery; Ovarian Neoplasms - therapy; Prognostic factor; Retrospective Studies
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2004.05.044

Objectives. To evaluate the clinical effect of intraperitoneal hyperthermic chemotherapy (IPHC) in ovarian cancer patients. Patients and methods. We retrospectively reviewed 117 stages Ic–III ovarian cancer patients, who were diagnosed at the Gynecology Department of Kangnam St. Mary's Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (conventional treatment) with IPHC and 60 patients (control group) underwent conventional treatment only. IPHC consisted of administering a mixture of 350 mg/m 2 of carboplatin and 5,000,000 IU/m 2 of interferon-α, and maintaining the intraperitoneal temperature at 43–44°C during surgery. Results. The overall 5-year survival rate was 58.6%; that of the IPHC group was 63.4% vs. 52.8% in the control group, with significantly higher survival in the IPHC group ( P = 0.0078). Considering stage III ovarian cancer patients only ( n = 74), the survival rate was 53.8% in the IPHC group ( n = 35) and 33.3% in the control group ( n = 39) and was significantly higher in the IPHC group ( P = 0.0015). For stage III ovarian cancer patients whose tumor was reduced to less than 1 cm during a second procedure ( n = 53), the 5-year survival rate was 65.6% in patients who underwent IPHC ( n = 26) and 40.7% in the control patients ( n = 27) ( P = 0.0046). IPHC was an independent prognostic factor that was not affected by surgical staging, tumor size after second surgery, or patient age, according to a multivariate analysis (Hazard ratio = 0.496, P = 0.0176). Conclusion. Our study suggests that IPHC is a promising new treatment modality in ovarian cancer.